DJ Team changes
Arix Bioscience PLC (ARIX)
Team changes
06-Jul-2021 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Team changes
LONDON, 06 July 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE: ARIX), a global venture capital company
focused on investing and building breakthrough biotech companies, today announces that Mark Chin will be re-joining the
Arix investment team as a Managing Director effective immediately.
Mark previously spent four years at Arix from 2016 to 2020 as an Investment Director. Mark sourced and led deals in key
Arix portfolio companies, including: VelosBio (acquired by Merck for USD2.75bn), Amplyx Pharmaceuticals (acquired by
Pfizer), Aura Biosciences, Harpoon Therapeutics (Nasdaq IPO) and Imara (Nasdaq IPO). He has extensive venture capital
expertise in early to late stage investing and significant experience as a board member, of both private and public
companies in the US and Europe. Since leaving Arix in 2020, Mark has remained a director of Harpoon Therapeutics, Inc.
(Nasdaq: HARP), Imara Inc. (Nasdaq: IMRA) and Iterum Therapeutics plc (Nasdaq: ITRM). Mark is based in New York and
will work to source and evaluate new investment opportunities and support existing venture investments through to exit.
Dr. Christian Schetter, Managing Director, has resigned from the investment team and will leave the Company on 31
August 2021. Dr. John Cassidy, Principal, had previously resigned from the investment team and will leave the Company
on 30 July 2021. Following the changes announced on 30 April 2021, the Board continues to develop the Company's
strategy and evaluate the appropriate team structure. The Board will work closely with Mark Chin to rebuild the
Company's investment team, adding new talent to deploy investment capital and manage the Company's existing portfolio.
After five years at Arix, Marcus Karia, Group Finance Director, will leave the Company later this year to pursue other
opportunities. Marcus will continue in his role until a search for his successor is completed.
Robert Lyne, Interim CEO of Arix, commented: "I am very pleased to welcome Mark back to Arix. Mark is a talented
investor and has played an instrumental role in the development of Arix, identifying and leading a number of high
quality investments, which have made a significant contribution to the strong performance across Arix's portfolio. Mark
will work closely with the Board to determine Arix's future investment strategy and will play a pivotal role in
building the investment team and shaping the Company's future.
"On behalf of the Company I would like to thank Christian, John and Marcus for their valuable contribution to Arix. We
wish them all the best for the future."
Mark Chin, Managing Director at Arix, added: "Biotech is now recognised as one the most important sectors to society:
the vaccine response to the pandemic and recent breakthroughs in oncology and other diseases underscore its disruptive
potential. Having seen first-hand the novel technologies Arix has fueled, and with the significant capital available to
us, I am excited to help identify and build the next generation of innovative biotech companies based on cutting-edge
science and world-class leadership."
Peregrine Moncreiffe, Chairman of Arix, commented: "The Board is determined to optimise Arix's contribution to the
biotech sector in Europe and the US and believes that its reconstituted investment team will generate superior
risk-adjusted returns for our shareholders."
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Mary Clark, Manel Mateus
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech
companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth
phase of our industry to a broader range of investors. www.arixbioscience.com
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 115436
EQS News ID: 1215445
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1215445&application_name=news
(END) Dow Jones Newswires
July 06, 2021 02:01 ET (06:01 GMT)
© 2021 Dow Jones News
